A targeted treatment for men with PSMA+ mCRPC
IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

 

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased ris...

See More
What is PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

 

  • has spread to other parts of the body (metastatic), and
  • has...
See More

mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.